Supernus Pharmaceuticals Cash on Hand 2012-2026 | SUPN
Supernus Pharmaceuticals cash on hand from 2012 to 2026. Cash on hand can be defined as cash deposits at financial institutions that can immediately be withdrawn at any time, and investments maturing in one year or less that are highly liquid and therefore regarded as cash equivalents and reported with or near cash line items.
|
Supernus Pharmaceuticals Annual Cash on Hand (Millions of US $) |
|
|---|---|
| 2024 | $454 |
| 2023 | $255 |
| 2022 | $461 |
| 2021 | $340 |
| 2020 | $423 |
| 2019 | $347 |
| 2018 | $356 |
| 2017 | $140 |
| 2016 | $90 |
| 2015 | $62 |
| 2014 | $74 |
| 2013 | $82 |
| 2012 | $89 |
| 2011 | $49 |
|
Supernus Pharmaceuticals Quarterly Cash on Hand (Millions of US $) |
|
|---|---|
| 2026-03-31 | $384 |
| 2025-09-30 | $281 |
| 2025-06-30 | $523 |
| 2025-03-31 | $464 |
| 2024-12-31 | $454 |
| 2024-09-30 | $403 |
| 2024-06-30 | $347 |
| 2024-03-31 | $298 |
| 2023-12-31 | $255 |
| 2023-09-30 | $200 |
| 2023-06-30 | $152 |
| 2023-03-31 | $632 |
| 2022-12-31 | $461 |
| 2022-09-30 | $392 |
| 2022-06-30 | $361 |
| 2022-03-31 | $312 |
| 2021-12-31 | $340 |
| 2021-09-30 | $444 |
| 2021-06-30 | $410 |
| 2021-03-31 | $391 |
| 2020-12-31 | $423 |
| 2020-09-30 | $352 |
| 2020-06-30 | $375 |
| 2020-03-31 | $401 |
| 2019-12-31 | $347 |
| 2019-09-30 | $297 |
| 2019-06-30 | $259 |
| 2019-03-31 | $293 |
| 2018-12-31 | $356 |
| 2018-09-30 | $280 |
| 2018-06-30 | $174 |
| 2018-03-31 | $490 |
| 2017-12-31 | $140 |
| 2017-09-30 | $115 |
| 2017-06-30 | $93 |
| 2017-03-31 | $87 |
| 2016-12-31 | $90 |
| 2016-09-30 | $80 |
| 2016-06-30 | $60 |
| 2016-03-31 | $45 |
| 2015-12-31 | $62 |
| 2015-09-30 | $58 |
| 2015-06-30 | $70 |
| 2015-03-31 | $65 |
| 2014-12-31 | $74 |
| 2014-09-30 | $73 |
| 2014-06-30 | $47 |
| 2014-03-31 | $59 |
| 2013-12-31 | $82 |
| 2013-09-30 | $87 |
| 2013-06-30 | $103 |
| 2013-03-31 | $70 |
| 2012-12-31 | $89 |
| 2012-09-30 | $61 |
| 2012-06-30 | $77 |
| 2012-03-31 | $38 |
| 2011-12-31 | $49 |
| 2011-09-30 | |
| 2011-06-30 | |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $2.918B | $0.719B |
| Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |